Bioheart To Introduce Improved Heart Failure Monitoring Systems At Heart Failure Nurses Annual Meeting

Main Category: Heart Disease
Also Included In: Cardiovascular / Cardiology;  Medical Devices / Diagnostics;  Conferences
Article Date: 19 Jun 2009 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced that the company will be introducing its heart failure monitoring systems at the American Association of Heart Failure Nurses 5th Annual Meeting. This year's meeting will take place from June 25 - 27, 2009 at the Hyatt Regency Minneapolis in Minneapolis, Minnesota.

The compact Bioheart 3370 home heart failure monitor engages patients through personalized daily interactions and questions, while collecting vital signs and transmitting the information directly into a database. The data are regularly monitored by remotely located medical professionals, who watch for any abnormal readings that may signal a change in the patient's health status. These changes are reported back to the treating physician or nurse. The monitor collects patient data from a range of monitoring devices such as weight scales and blood pressure monitors. Regular data input and monitoring of heart failure patients enables the health care team to detect signs and symptoms of change as they occur leading to reduced re-hospitalizations, reduced costs and better patient outcomes.

Bioheart worked closely with leading heart failure physicians to design the best possible program for patients. "We believe our heart failure monitoring program is best-in-class and that it will lead to improved patient care and a substantial reduction of costs to the healthcare system," said Howard J. Leonhardt, the companies Chief Executive Officer. "We have developed a proactive patient care strategy based on the early recognition of symptoms and early intervention before things progress to a hospitalization."

About Bioheart, Inc.

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

Source: Bioheart, Inc